Inventory of Pharmaceutical Enterprises' Advertising Expenditure in the First Half of 2014

Release time:


Kantar Media is a well-known media research and insight department. According to its latest data, in the first half of 2014, pharmaceutical companies put a total of US $0.342 billion billion in advertisements in professional medical journals, an increase of 1% over the same period.
2014 is a year of resource integration. In 2015, it is a year when the traditional field of biopharmaceuticals knows more about "Internet thinking digital media.
Taking stock of the past years in 2014, we found that Johnson & Johnson (Johnson & Johnson) invested US $23 million in advertising in the first 6 months alone, and it is also the largest consumer of advertising investment in the pharmaceutical industry.
GlaxoSmithKline (GSK), which has been the subject of a "bribery and corruption" scandal, invested $9 million, less than half that of Johnson & Johnson, but up 110 percent from 2013 to rank second.
Pfizer (Pfizer) fell from the same period last year, and its investment was similar to Takeda (Takeda) at $8 million, while Novartis (Novartis) ranked fifth at $7 million.
And this ranking, compared with the whole year of last year, Johnson & Johnson has always maintained its advertising investment in the industry. 1 status.
The difference is that Forest Labs (Forest Laboratories) spent more on advertising in 2013, and in February this year, the world's third-largest generic drug manufacturer, Actavis PLC (NYSE:ACT) announced that it had acquired brand drug manufacturer Forest Labs (Forest Laboratories) for about $25 billion in a cash and stock transaction.
The following is a comparison list of advertising expenditure of pharmaceutical companies in the first half of 2014 and the expenditure of the whole year of 2013:

Kantar Media research shows that the purchase of flat media advertising pages in medical journals has dropped by 2% every year to reach 53094 US dollars, which has something to do with the rise of online media.
On the basis of treatment, oncology drug brands led consumption, with oncology drug brands investing $25 million, accounting for 7% of the total market share, followed by oral diabetes drugs ($14 million), up 52% from the same period last year, accounting for 4% of sales.